Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Candesartan Cilexetil 32 mg in Healthy Adults
NCT04012307Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of candesartan cilexetil in hypertension (HTN) and heart failure (HF) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve from time 0 to the last measurable concentration at 48 hours. Started Jul 2019; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT04012307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012307.